CAS: 9050-31-1; Hydroxypropylmethylcellulosephthalate

该化合物是一种纤维素衍生物,通常用于制药和食品应用中,作为一种肠内涂层剂,其特点是能够制作一部在碱性条件下可溶解的薄膜,保护敏感活性成分免受胃酸,同时确保其在肠中中性pH中释放.HPMCP通常通过对含有phthalic an-hydilide的甲基丙醇氢丙基甲基纤维素进行酯化生产,从而形成一种具有良好热稳定性和胶片成型特性的复合物.一般认为,它对于食品和药品的使用是安全的(GRAS),其溶性可以通过调整氢丙基和甲基组的替代程度加以调整.除了在涂料中使用外,HPMCP还可在各种配方中用作增厚剂和稳定剂.其多变性和生物兼容性使它成为制药和食品工业中的宝贵成分.

结构式图片

欧盟法规

C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-12188072-B2
    优先权日:2018-03-19
    标题 :Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
    发明人:JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
    权利人:UNIV NORTHWESTERN; UNIV CORNELL
    摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

    专利号:US-12365930-B2
    优先权日:2016-07-14
    标题:Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
    发明人:JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
    权利人:UNIV NORTHWESTERN; UNIV CORNELL
    摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

    专利号:US-12221452-B2
    优先权日:2017-10-04
    标题:Synthesis of cantharidin
    发明人:DAVIDSON MATTHEW GENE; EKLOV BRIAN MATTHEW; WUTS PETER; LOERTSCHER BRAD MELVIN; SCHOW STEVEN R
    权利人:VERRICA PHARMACEUTICALS INC
    摘要:The invention provides synthetic methods for the preparation of cantharidin and analogs thereof. In one aspect, the invention provides an improved Diels-Alder cycloaddition to generate a key intermediate en route to cantharidin and analogs thereof. In certain embodiments, the new Diels-Alder reaction involves reacting Compound (2) in the presence of furan, and in the absence of acid or increased pressure, in an aprotic polar solvent with slight warming, to yield Compound (1) in favorable yield and exo-endo ratio. In another aspect, the invention also provides a new Diels-Alder reaction between compounds of Formula (III) and furan to yield compounds of Formula (IV), which can then be transformed into cantharidin or analogs thereof. In yet another aspect, the invention describes a new palladium-mediated carbonylation providing another key intermediate en route to cantharidin and analogs thereof. In addition to synthetic methods, present invention also provides compounds (i.e., intermediates) useful in the synthesis of cantharidin and analogs thereof. Compounds provided herein may have biological activity, and therefore may be used in the treatment of diseases or conditions (e.g., infectious diseases and skin conditions).

    专利号:US-12391691-B2
    优先权日:2018-11-16
    标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
    发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
    权利人:AMGEN INC
    摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

    专利号:EP-0310950-B1
    优先权日:1983-11-18
    标题 :Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes
    摘要:Compounds of the types (I) and (II) are disclosed, wherein each R5 is independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms and halogen, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R5 substituents together contain no more than 6 carbon atoms; R6 is selected from the group consisting of hydroxyalkyl of one to about six carbon atoms and cyclohexylmethyl; and R7 is selected from the group consisting of alkyl of one to about four carbon atoms and hydrogen. These compounds may be used as intermediates for the synthesis of 1H-imidazo[4,5-c]quinoline derivatives.

    专利号:US-2025206736-A1
    优先权日:2019-11-14
    标题 :Synthesis of kras g12c inhibitor compound
    发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
    权利人:AMGEN INC
    摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
    西安天正药用辅料有限公司
    小微企业
    注册号: 916101040973741477 法定代表人:刘少美
    注册资本:150万人民币类型:有限责任公司(自然人投资或控股)
    成立日期:2014-04-11 登记机关:西安市莲湖区市场监督管理局
    注册地址: 陕西省西安市莲湖区劳动路138号南楼306号
    药用辅料、医药中间体、食品添加剂、精细化学品(不含易燃易爆易制毒危险品)、化学试剂及化工原料(不含易燃易爆易制毒危险品)、动植物提取物、生物制品、农副产品的销售;食品、保健食品、保健用品、化妆品、消毒产品、消毒用品的生产、销售;货物及技术的进出口业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
    免费会员贸易
    https://www.tzyaofu.com
    企业联系电话:029-88777016👤
    📞 西安天正药用辅料有限公司 联系方式
    销售经理: 王再峰 / 杨雅茹
    手机号: 15667068820 / 18509256165
    QQ: 381969247
    QQ: 33405760195
    微信1: 15667068820
    微信2: 18509256165
    ⚠️ 声明: 咨询或交易时请注意风险评估和信息核实,百琢研不参与任何交易。

    地址:陕西省西安市莲湖区劳动路138号南楼306号
    常规和库存产品150产品总量: 219
    西安天正药用辅料logo
    平台资质认证✓营业执照✓
    JBOC建标认证
    图片邻苯二甲酸羟丙甲纤维素酯
    质量标准: 药典四部
    最小包装:500g或1kg一袋; 大包装:25kg/桶或20kg一箱;
    备注: 有需要其他品种,可以电话联系或者qq联系!
    湖州展望药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zhanwangpharma.com
    电话: 0572-3942328 3943554👤
    📞湖州展望药业股份有限公司 ⚠️参考联系方式

    销售电话:0572-3942328 3943554
    邮箱:sales@zhanwangpharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北兴琰新材料科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hbxyxcl.com
    企业联系电话:15927421338👤
    📞湖北兴琰新材料科技有限公司 ⚠️参考联系方式
    联系人:覃化
    电话:15927421338
    手机:15927421338

    邮箱:15927421338@chemnet.com
    通信地址: 湖北省武汉市东湖新技术开发区东二产业园财富二路8号
    邮编: 430000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北省武汉市东湖新技术开发区东二产业园财富二路8号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    泰安瑞泰新材料股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.ruitai.com
    电话: 0538-5383850186👤
    📞泰安瑞泰新材料股份有限公司 ⚠️参考联系方式

    销售电话:0538-5383850186
    邮箱:sales@ruitai.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.5021/ad.2011.23.2.229
    摘要:Seo SH, Kim GW, Sung HW. Imiquimod as an adjuvant treatment measure for desmoplastic trichoepithelioma. Ann Dermatol. 2011 May;23(2):229–31.
    参考文献:10.1155/2011/269515
    摘要:Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, Yousefzadeh H. Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. Dermatology Research and Practice. 2011;2011():1–4. doi: 10.1155/2011/269515.
    参考文献:10.1371/journal.pone.0021756
    摘要:Carroll TD, Matzinger SR, Fritts L, McChesney MB, Miller CJ. Memory B Cells and CD8+ Lymphocytes Do Not Control Seasonal Influenza A Virus Replication after Homologous Re-Challenge of Rhesus Macaques. PLoS ONE. 2011 Jun 29;6(6):e21756. doi: 10.1371/journal.pone.0021756.
    参考文献:10.1007/s10637-011-9717-2
    摘要:Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs. 2012 Aug;30(4):1641–5. doi: 10.1007/s10637-011-9717-2.
    参考文献:10.1007/s10103-011-0952-8
    摘要:Ballard CJ, Rivas MP, McLeod MP, Choudhary S, Elgart GW, Nouri K. The pulsed dye laser for the treatment of basal cell carcinoma. Lasers Med Sci. 2011 Sep;26(5):641–4. doi: 10.1007/s10103-011-0952-8.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知